

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K		(11) International Publication Number: WO 00/61068
		(43) International Publication Date: 19 October 2000 (19.10.00)
<p>(21) International Application Number: PCT/NZ00/00053</p> <p>(22) International Filing Date: 14 April 2000 (14.04.00)</p> <p>(30) Priority Data: 335166 14 April 1999 (14.04.99) NZ</p> <p>(71) Applicant (<i>for all designated States except US</i>): ASHMONT HOLDINGS LIMITED [NZ/NZ]; 48 Diana Drive, Glenfield, Auckland 1310 (NZ).</p> <p>(72) Inventor; and</p> <p>(75) Inventor/Applicant (<i>for US only</i>): COLIN, Manson, Harvey [NZ/NZ]; 55 Beach Road, Castor Bay, Auckland 1309 (NZ).</p> <p>(74) Agents: PIPER, James, William et al.; Pipers, P.O. Box 5298, Wellesley Street, Auckland 1036 (NZ).</p>		<p>(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>Without international search report and to be republished upon receipt of that report.</i></p>
<p>(54) Title: ANTHELMINTIC COMPOSITION</p> <p>(57) Abstract</p> <p>The invention relates to a novel formulation having the advantage of including triclabendazole in solution. In addition a further anthelmintic may be included. The formulation is made by mixing the abamectin and benzyl alcohol and mixing this with triclabendazole and butyl dioxitol. The mix is then heated to dissolve the active, and allowed to cool at which stage the solution is diluted to volume with PEG 4000. The present invention overcomes the solubility difficulties of triclabendazole and presents the triclabendazole in a solution.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

ANTHELMINTIC COMPOSITION**FIELD OF THE INVENTION**


This invention relates to novel anthelmintic formulations and in particular it relates to stable veterinary formulations containing the anthelmintic triclabendazole.

5

BACKGROUND

The benzimidazoles, including triclabendazole, are well known for their anthelmintic activity. Of all the benzimidazoles known, triclabendazole is particularly useful, as it is highly effective against liver flukes 10 at all stages of their life cycle. Albendazole, in contrast, is only effective against adult flukes.

Triclabendazole, is also known as 5-Chloro-6-(2,3-dichlorophenoxy)-2-methylthio-1H-benzimidazole, and represented by Formula I.



Ruminants, such as sheep, cattle and goats, are susceptible to *Fasciola*, the disease caused by parasitic liver flukes, and it is important that formulations effective against the disease are available. In particular 20 it is advantageous to have liquid formulations which contain the active anthelmintic in solution and which are easily administered by way of a pour-on.

It has been difficult to provide liquid formulations containing triclabendazole due to the highly insoluble nature of the compound. This has resulted in anthelmintic formulations containing triclabendazole 25 being prepared as suspensions. Suspension formulations have a number of disadvantages. The most serious relates to stability. Veterinary formulations may be stored for extended periods in large, opaque containers and must be stable. Suspensions tend to be unstable in that the actives tend to settle out of the formulation. This causes problems as it results in differences in concentration of the active through the formulation. This in turn leads to difficulties in determining the effective and safe doses for

treatment of livestock. Suspensions are also less able to be absorbed when applied by way of a pour-on. Pour-ons must be formulated to penetrate the skin which is the body's natural barrier. While a suspension may be absorbed from the digestive tract the same formulation applied to the skin would be less able to be absorbed. By developing suitable liquid formulations particularly with solvents which
5 have a good affinity for penetrating skin the active is more likely to be absorbed. With most actives applied as pour-ons to the dermis the dose rate at which it is applied is increased when compared to an oral or injectable formulation. This is to make up for the less efficient absorption through skin tissues.

OBJECT

10

It is an object of the invention to provide an improved stable liquid anthelmintic solution containing an effective amount of triclabendazole which is suitable for administration to warm blooded animals or one which at least provides the public with a useful choice.

15 STATEMENT OF INVENTION

In one aspect the invention provides a stable liquid veterinary formulation containing an effective amount of triclabendazole wherein the triclabendazole is dissolved in at least one solvent.

20 Preferably the invention relates to a stable liquid veterinary formulation suitable for administration by pour-on.

25 Preferably the solvent is selected from the group including benzyl alcohol, glycerol formal, n-methyl-2-pyrrolidone, glycol ethers such as butyl dioxitol (also known as Dipropylene glycol methox ether) and related isomers and aromatic solvents such as xylene or toluene.

Most preferably the solvent is at least one of benzyl alcohol and glycerol formal.

30 More preferably the stable liquid veterinary pour-on formulation includes triclabendazole present in the range 10-40% w/v.

Preferably the formulation may include at least one additional anthelmintic selected from the group avermectins, milbemycins, tetramisole and levamisole, which is soluble in the pour-on formulation of this present invention.

Most preferably the additional anthelmintic is selected from the avermectins.

Most preferably avermectin is also present in the range 0.25-2 % w/v.

5

In another related aspect the invention relates to a method of treating warm blooded animals for parasites by administering to said animal a formulation of the present invention.

10 In another related aspect the invention relates to a method of treating liver flukes in warm blooded animals by administration of pour-on formulation.

PREFERRED EMBODIMENTS

15 It has now been found that stable liquid formulations containing the active triclabendazole in solution can be prepared and that these actives can be absorbed through the skin to control the infection of liver in animals in particular cattle.

The above, and other aspects of the invention, which should be considered in all its novel aspects will be apparent from the following examples.

20

EXAMPLE 1

The formulation of this example is shown in table 1. It is suitable for administration as a pour-on, in particular to cattle. The recommended dose rate is:

25

Table 1

INGREDIENT	g/100mL
Abamectin	0.5
Triclabendazole	30.0
Butyl dioxitol	50.0
Benzyl Alcohol	5.0
PEG 400	to volume

To prepare the formulation add the abamectin and benzyl alcohol. To this add butyl dioxitol and the triclabendazole. Warm to 40°C and stir to dissolve. Cool mix to less than 25°C and dilute to volume with PEG 400. It will be apparent to the skilled addressee if filtering is necessary at this point.

5 TRIALS

Stability Trials

A stability trial was conducted to ensure that the triclabendazole solution was stable. A formulation made as described in example 1 ("Formulation 1") was stored at ambient for 11 months. At the 10 conclusion of the storage period samples were tested for total abamectin and triclabendazole levels. The results are presented in table 2 below.

Table 2: Stability Trial Formulation 1

	Abamectin B1 _a	Abamectin B1 _b	Total Abamectin	Triclabendazole
Date of manufacture Day 1	0.48	0.02	0.50	31.3
End of trial Day 345	0.48	0.008	0.49	28.9

Method	Reference	Technique
Abamectin	H127/01V3	HPLC
Triclabendazole	In House	HPLC

15 The results clearly show that the triclabendazole remained in solution. There was no loss in activity for either abamectin or triclabendazole.

Efficacy Trials

Trials were conducted comparing the efficacy of the Formulation 1 with two other treatments and a 20 control. The trial included twenty animals all confirmed infected with *Fasciola* spp. The animals were divided into four groups of five animals. The animals were ranked on the basis of faecal fluke egg counts, and divided into blocks of four. Animals from each block were randomly allocated to one of the four treatment groups. Egg counts were performed twice on animals a week prior to the trial to confirm all animals had a *Fasciola* spp burden. At day zero of the trial all animals were treated according to the

protocol set out in Table 3. Group 1 animals were left untreated as controls. Group 2 received Formulation 1. Group 3 were the positive control group and received a commercial flukicide Fasinex 50 (Novartis). Group 4 received triclabendazole oral formulations at levels shown in table 3.

During the course of the trial all animals were grazed as a single group grazing on fluke infested 5 pastures up to treatment and then removed to fluke free pastures post treatment.

Table 3

Group 1	No treatment
Group 2	At 5ml per 50kg topically with the pour-on of Formulation 1
Group 3	At 12ml per 50kg orally with Fasinex 50 50mg per ml of triclabendazole
Group 4	At 12ml per 50kg orally with the triclabendazole oral drench containing 50mg per ml of triclabendazole

- At 14 days post treatment all animals were sacrificed. Total worm counts were performed using the 10 following procedures:
1. Faecal egg counts
 2. *Fasciola hepatica* liver counts. The liver counts were performed by collecting the entire liver (ensuring the gall bladder remained intact) at necropsy. The liver was then labelled and 15 transported (within 4 hours) on ice to laboratory facilities.
 3. The liver was laid on a smooth surface and was evaluated for gross pathological changes according to the morbid pathology score sheets.
 4. Large bile ducts and gall bladder were dissected allowing the mature and larger immature fluke if present to be seen. These were counted and recorded on sheets. The balance of the liver 20 tissue is dissected into 1cm thick slices and gently squeezed between the fingers. Any immature fluke appearing from the tissue were retrieved and countered. Remaining tissue was homogenised in a tissue "Stomacher" and washed over a 20 micron mesh such that any remaining immature flukes were recovered. The total worm counts were collated into the treatment groups.
- 25 Effective control was obtained against an established natural *Fasciola hepatica* burden with all formulations. The results are summarised on table 4 below.

Table 4: Total Worm Counts

<i>Treatment</i>		<i>Adult Fasciola hepatica</i>	<i>Immature Fasciola hepatica</i>
Control	mean -	20 n/a	4.3 n/a
Formulation 1	mean	0	0
	% reduction	100	100
Fasinex 50	mean	0	0
	% reduction	100	100
TCB formulation	mean	0	0
	% reduction	100	100

It can be clearly seen from the trials that the formulations of the present invention provide effective treatment of infection by the parasite *Fasciola hepatica*.

5

In addition the formulations of the present invention provide the advantage of increased stability over the previous suspension formulations.

The combination of increased stability and effective treatment against all stages of *Fasciola hepatica* is 10 a real advantage. It allows the storage of formulation for long periods as may arise in veterinary practises or on the farm eliminating wastage. In addition it eliminates the problems caused by settling of actives. The maintenance of the actives in solution and therefore maintaining a uniform concentration across the formulation ensuring an effective safe dose on application at the recommended dosage.

15 ADVANTAGES

It is advantageous to be able to provide triclabendazole in stable solutions which can be more easily and effectively administered by pour-on. These solutions also allow the use of triclabendazole in combination with other anthelmintics resulting in broader spectrum of activity, and consequently a 20 reduction in the number of treatments required. Now that triclabendazole can be dissolved to form a stable pour-on solution the opportunities for combining this effective anthelmintic with other actives in stable solutions have substantially increased.

VARIATIONS

It is envisaged that the formulations are the subject of the invention may be modified by the inclusion of additional excipients without departing from the spirit and scope of the invention.

5

In particular it may be desirable to include dyes in the formulation to allow easy identification of treated animals. Alternately other excipients such as buffers, thickeners, spreading agents may be included to modify the formulation to specific animals.

- 10 Finally it will be appreciated that various other alterations and modifications may be made to the foregoing without departing from the scope of the invention.

CLAIMS:

1. A stable liquid veterinary formulation containing an effective amount of triclabendazole
5 wherein the triclabendazole is dissolved in at least one solvent.
2. A stable liquid veterinary formulation as claimed in claim 1, which is suitable for administration by pour-on.
- 10 3. A stable liquid veterinary formulation as claimed in any previous claim wherein the solvent is selected from the group including benzyl alcohol, glycerol formal, n-methyl-2-pyrrolidone, glycol ethers and aromatic hydrocarbons.
- 15 4. A stable liquid veterinary formulation as claimed in any previous claim, wherein the solvent is at least one of benzyl alcohol and glycerol formal.
5. A stable liquid veterinary formulation as claimed in any previous claim wherein the triclabendazole is present in the range 10-40% w/v.
- 20 6. A stable liquid veterinary formulation as claimed in any previous claim which includes at least one additional anthelmintic selected from the group avermectins, milbemycins, tetramisole and levamisole, which is soluble in the pour-on formulation of the present invention.
- 25 7. A stable liquid veterinary formulation as claimed in any previous claim wherein the additional anthelmintic is an avermectin.
8. A stable liquid veterinary formulation as claimed in any previous claim, wherein the avermectin is present in the range 0.25 - 2 % w/v.
- 30 9. A method of treating warm blooded animals for parasites by administering to said animal a formulation as claimed in any previous claim.
10. A method of treating liver flukes in warm blooded animals by administration of pour-on formulation as described in any previous claim.